TMT-based proteomic analysis reveals integrins involved in the synergistic infection of reticuloendotheliosis virus and avian leukosis virus subgroup J.
Avian leukosis virus subgroup J
Reticuloendotheliosis virus
Synergistic infection
TMT proteomic analysis
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
04 Apr 2022
04 Apr 2022
Historique:
received:
03
11
2021
accepted:
09
03
2022
entrez:
5
4
2022
pubmed:
6
4
2022
medline:
7
4
2022
Statut:
epublish
Résumé
Co-infection with the avian leukosis virus subgroup J (ALV-J) and the reticuloendotheliosis virus (REV) increases mutual viral replication, causing a more serious pathogenic effect by accelerating the progression of neoplasia and extending the tumor spectrum. However, the molecular mechanism underlying the synergistic replication of ALV-J and REV remains unclear. Here, we performed this study to compare the differentially expressed proteins among CEF cells infected with ALV-J, REV or both at the optimal synergistic infection time using TMT-based quantitative proteomics. We identified a total of 719 (292 upregulated and 427 downregulated) and 64 (35 upregulated and 29 downregulated) proteins by comparing co-infecting both viruses with monoinfecting ALV-J and REV, respectively. GO annotation and KEGG pathway analysis showed the differentially expressed proteins participated in virus-vector interaction, biological adhesion and immune response pathways in the synergistic actions of ALV-J and REV at the protein levels. Among the differentially expressed proteins, a large number of integrins were inhibited or increased in the co-infection group. Further, eight integrins, including ITGα1, ITGα3, ITGα5, ITGα6, ITGα8, ITGα9, ITGα11 and ITGβ3, were validated in CEF cells by qRT-PCR or western blot. These findings proved that integrins may be key regulators in the mechanism of synergistic infection of REV and ALV-J, which will provide more insight into the pathogenesis of synergism of REV and ALV-J at protein level.
Sections du résumé
BACKGROUND
BACKGROUND
Co-infection with the avian leukosis virus subgroup J (ALV-J) and the reticuloendotheliosis virus (REV) increases mutual viral replication, causing a more serious pathogenic effect by accelerating the progression of neoplasia and extending the tumor spectrum. However, the molecular mechanism underlying the synergistic replication of ALV-J and REV remains unclear.
RESULTS
RESULTS
Here, we performed this study to compare the differentially expressed proteins among CEF cells infected with ALV-J, REV or both at the optimal synergistic infection time using TMT-based quantitative proteomics. We identified a total of 719 (292 upregulated and 427 downregulated) and 64 (35 upregulated and 29 downregulated) proteins by comparing co-infecting both viruses with monoinfecting ALV-J and REV, respectively. GO annotation and KEGG pathway analysis showed the differentially expressed proteins participated in virus-vector interaction, biological adhesion and immune response pathways in the synergistic actions of ALV-J and REV at the protein levels. Among the differentially expressed proteins, a large number of integrins were inhibited or increased in the co-infection group. Further, eight integrins, including ITGα1, ITGα3, ITGα5, ITGα6, ITGα8, ITGα9, ITGα11 and ITGβ3, were validated in CEF cells by qRT-PCR or western blot.
CONCLUSIONS
CONCLUSIONS
These findings proved that integrins may be key regulators in the mechanism of synergistic infection of REV and ALV-J, which will provide more insight into the pathogenesis of synergism of REV and ALV-J at protein level.
Identifiants
pubmed: 35379256
doi: 10.1186/s12917-022-03207-6
pii: 10.1186/s12917-022-03207-6
pmc: PMC8978386
doi:
Substances chimiques
Integrins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
131Informations de copyright
© 2022. The Author(s).
Références
Acta Virol. 1999 Apr-Jun;43(2-3):136-42
pubmed: 10696434
Cell Tissue Res. 2001 Sep;305(3):285-98
pubmed: 11572082
Curr Opin Virol. 2018 Oct;32:48-59
pubmed: 30268926
Expert Rev Anti Infect Ther. 2015 Aug;13(8):947-63
pubmed: 26112187
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26
pubmed: 15459662
Carcinogenesis. 2016 Dec;37(12):1117-1128
pubmed: 27664164
Pan Afr Med J. 2018 May 28;30:61
pubmed: 30344845
Cell. 1992 Apr 3;69(1):11-25
pubmed: 1555235
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Folia Biol (Praha). 2004;50(5):143-52
pubmed: 15581065
Nat Rev Mol Cell Biol. 2019 Aug;20(8):457-473
pubmed: 31182865
J Virol. 2016 Jul 27;90(16):7303-7312
pubmed: 27252538
J Proteomics. 2020 Aug 15;225:103876
pubmed: 32534212
Avian Pathol. 2015;44(1):43-9
pubmed: 25484188
Front Immunol. 2021 May 04;12:604222
pubmed: 34040601
Biosci Rep. 2017 Apr 10;37(2):
pubmed: 28302677
J Mol Biol. 2018 Aug 17;430(17):2590-2611
pubmed: 29924965
Avian Pathol. 2009 Dec;38(6):443-8
pubmed: 19937533
Nucleic Acids Res. 2019 Jan 8;47(D1):D1211-D1217
pubmed: 30252093
Int J Mol Sci. 2020 Dec 21;21(24):
pubmed: 33371194
Trends Genet. 2000 Sep;16(9):389-95
pubmed: 10973067
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
J Virol. 1995 Feb;69(2):779-84
pubmed: 7815543
Onco Targets Ther. 2016 Apr 18;9:2317-27
pubmed: 27143927
Retrovirology. 2018 Jul 3;15(1):45
pubmed: 29970099
Virulence. 2020 Dec;11(1):1158-1176
pubmed: 32799626
Virology. 2017 Apr;504:45-51
pubmed: 28152383
Nucleic Acids Res. 2021 Jan 8;49(D1):D545-D551
pubmed: 33125081
Sci Rep. 2019 Feb 26;9(1):2793
pubmed: 30808960
Exp Cell Res. 2019 Jan 1;374(1):85-93
pubmed: 30458180
Nat Rev Cancer. 2002 Feb;2(2):91-100
pubmed: 12635172
Retrovirology. 2017 Dec 2;14(1):55
pubmed: 29197389
Nat Rev Cancer. 2010 Jan;10(1):9-22
pubmed: 20029421
J Gen Virol. 1991 Apr;72 ( Pt 4):801-7
pubmed: 1849967
Curr Opin Virol. 2016 Dec;21:81-86
pubmed: 27580489
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
Cell Immunol. 2011;267(1):56-66
pubmed: 21145045
AIDS Rev. 2007 Jul-Sep;9(3):140-9
pubmed: 17982939
Arch Virol. 2015 Nov;160(11):2669-81
pubmed: 26321473
Med Oncol. 2016 Jul;33(7):75
pubmed: 27287342
Exp Cell Res. 2021 Oct 15;407(2):112815
pubmed: 34496296
Am J Transl Res. 2015 Sep 15;7(9):1564-73
pubmed: 26550456